Goldman Sachs noted that the stock is trading near all-time highs, in alignment with global peers. Robust nominal growth in the earnings of Indian listed firms and an expected 11 per cent compound ...

Inspired by their 9-month old son William, who was diagnosed with ALD after a newborn screening, the Hall family seeks to jumpstart research into the rare disease, in partnership with The Dallas ...

Mesoblast (ASX:MSB) was the top performer for the year up 835% (as of December 30). On December 18 Mesoblast announced that the US Food and Drug Administration (FDA) had finally approved its therapy ...